Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sacituzumab Tirumotecan + Pembrolizumab in pMMR Endometrial Cancer
NCT06952504Phase 3Recruiting
- Sponsor
- Merck & Co.
- Start
- May 2025
- Primary completion
- May 2032
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 34
01
Overview
A Phase 3 trial of sacituzumab tirumotecan in endometrial cancer (EC), sponsored by Merck & Co.. Started May 2025; status: recruiting.
02
Drugs
sacituzumab tirumotecan
03
Conditions
endometrial cancer (EC)
Beyond the preview
Go deeper on NCT06952504.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06952504.